#AIEye
#Podcast 714: #Stocks discussed: (OTCPINK: $GTCH) (NYSE: $PLTR) #artificialintelligence
GBT
Releases New Version of Hippocrates Web App, and Palantir Announces $99.9M
Contract with US Army Research Lab for AI/ML
Global
#AI in #DrugDiscovery to Reach $4B by 2027
Vancouver, Kelowna,
Delta, BC – July 28, 2022
– Investorideas.com, a
global investor news source covering Artificial Intelligence (AI) brings
you today’s edition of The
AI Eye-watching stock news, deal tracker and advancements in
artificial intelligence – featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).
Listen
to today’s podcast:
https://www.investorideas.com/Audio/Podcasts/2022/072822-AI-Eye.mp3
Read
this in full at https://www.investorideas.com/news/2022/artificial-intelligence/07281GTCH-PLTR.asp
Today’s
Column- The
AI Eye- Watching stock news, deal tracker and advancements
in artificial intelligence
Stocks
discussed: (OTCPINK:GTCH) (NYSE:PLTR)
GBT Technologies Inc. (OTC PINK:GTCH) has announced that it is releasing a new version
of the web application for its Hippocrates machine learning driven health
content provider. The new application will leverage the company’s Avant! AI
engine to “provide intelligent internet search, providing answers for general
or specific health related questions.” Danny Rittman, GBT’s CTO, explained:
"This
is only one of the many possible implementations of our core Avant! AI
technology. The AI system is targeted to understand a user's question,
analyzing the information and providing a targeted response. Hippocrates' new
release is equipped with an initial vast amount of health-related data and is
situated to cognitively grow its knowledge base over time, learning from its
own experiences or by training, the same way a human does. We invested vast
efforts with the new release, incorporating professional, accredited data from
governmental and medical documentation resources. The current release is aimed
to provide a first line of health-related information. In addition, it offers
Avant! intelligent internet search to provide answers and information for
health-related questions. The system is not aiming to replace physicians but to
provide first line health information and guidelines. We also plan to seek
clinics and hospitals as partners to provide an expert assistant in specific
domains, for example cardiology or pediatrics expertise.”
Palantir Technologies Inc. (NYSE:PLTR) has announced a two-year contract worth $99.9
million USD with the U.S. Army Research Laboratory to implement data and
artificial intelligence (AI)/machine learning (ML) capabilities for users
across the combatant commands (COCOMs). Akash Jain, President of Palantir USG,
said:
"Maintaining
a leading edge through technology is foundational to our mission and
partnership with the Army Research Laboratory. Our nation’s armed forces
require best-in-class software to fulfill their missions today while rapidly
iterating on the capabilities they will need for tomorrow’s fight. We are
honored to support this critical work by teaming up to deliver the most
advanced operational AI capabilities available with dozens of commercial and
public sector partners."
Global
AI in Drug Discovery to Reach $4B by 2027
A report published by Markets and Markets finds that the global AI
in Drug Discovery market is projected to grow from $600 million USD in 2022 to
$4 billion by 2027, registering a compound annual growth rate (CAGR) of 45.7
percent in the forecast period. The following excerpt from the report’s description
outlines the significance of Deep Learning as a driving aspect of the market:
Based
on type, the machine learning technology segment further segmented into deep
learning, supervised learning. reinforcement learning, unsupervised learning,
and other machine learning technologies. Deep learning segment accounted for
the largest share of the market in 2021, and this segment is also expected to
grow at the highest CAGR during the forecast period. Deep learning helps in
managing data in a consistent manner, saves time, reduces the chances of errors
in the drug discovery process, and reduces the workload for end users are some
of the key factors for the market growth of this segment.
Sam Mowers,
Investorideas.com
Read and hear other editions of the
AI Eye
For a list of artificial intelligence stocks
on Investorideas.com visit here
About Investorideas.com -
News that Inspires Big Investing Ideas
Investorideas.com
publishes breaking stock news, third party stock research, guest posts and
original articles and podcasts in leading stock sectors. Learn about investing in stocks and get
investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy, gaming and more. Investor Idea’s original branded content
includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the
Move podcast , Cleantech and Climate
Change , Exploring Mining , Betting on Gaming Stocks
Podcast and the AI Eye Podcast.
The Investorideas.com
podcasts are also available on Apple Podcasts ,
Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google
Podcasts and most audio platforms available.
Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each
company directly regarding specific questions.
Disclosure: GTCH is a paid for AI featured stock on our
site. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and
our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
The AI Eye- Watching stock news, deal tracker and
advancements in artificial intelligence is an original content brand of
Investorideas.com
Follow us
on Twitter https://twitter.com/Investorideas
Follow us
on Facebook https://www.facebook.com/Investorideas
Follow us
on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800 665 0411
Get
more Technology stock investor
ideas -
news, articles, podcasts and stock directories
No comments:
Post a Comment